From 2014 all new branded drugs will be subject to a revised
process of drug pricing known as value-based pricing. Prostate
Cancer UK and thirteen other leading cancer charities are working
together to help shape this change rather than simply watching it
develop unchallenged. We commissioned research to ensure the views
of people affected by cancer are put at the heart of the
Government's new drug pricing policy.
Our report -
Value-based pricing: Getting it right for people with
cancer - sets out our key recommendations based on the
findings of this research. We believe that our recommendations
have an important role to play in ensuring that the new value-based
pricing system genuinely reflects the needs and aspirations of the
millions of people affected by cancer in the UK.
Working together
We look forward to working closely with the Government, the
pharmaceutical industry and other key stakeholders in the coming
months to bring about a system which genuinely reflects the views
of people affected by cancer and the recommendations in this
report.
Read Chief Executive Owen Sharp's latest blog entry on the
importance of getting value-based
pricing right.
You can view the appendices of the report by clicking on the
links below.
Appendix 1
Appendix 2
Appendix 3
Appendix 4
Appendix 5
Appendix 6